Research Papers

Below are a range of selected publications within the fields of epilepsy, psychosis, metabolic syndrome and cancer that provide further pharmacologic background to these avenues of research:

 Epilepsy

 

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Porter BE, Jacobson C. Epilepsy Behav. 2013 Dec;29(3):574-7.

 

Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.

Amada N, Yamasaki Y, Williams CM, Whalley BJ. PeerJ. 2013 Nov 21;1:e214.

 

Cannabidivarin is anticonvulsant in mouse and rat.

Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, Futamura T, Duncan M, Stott CG, Stephens GJ, Williams CM, Whalley BJ. Br J Pharmacol. 2012 Dec;167(8):1629-42.

 

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures

Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, Burnett MD, Yamasaki Y, Stephens GJ, Whalley BJ, Williams CM.Seizure. 2012 Jun;21(5):344-52

 

Phytocannabinoids as novel therapeutic agents in CNS disorders

Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Pharmacol Ther. 2012 Jan;133(1):79-97

 

Δ⁹-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats

Hill AJ, Weston SE, Jones NA, Smith I, Bevan SA, Williamson EM, Stephens GJ, Williams CM, Whalley BJ. Epilepsia. 2010 Aug;51(8):1522-32.

 

Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo

Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ. J Pharmacol Exp Ther. 2010 Feb;332(2):569-77.

 

The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum 

Ma YL, Weston SE, Whalley BJ, Stephens GJ. Br J Pharmacol. 2008 May;154(1):204-15.

 

 

Diabetes / Metabolic Disease

 

The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.

Wargent ET, Zaibi MS, Silvestri C, Hislop DC, Stocker CJ, Stott CG, Guy GW, Duncan M, Di Marzo V, Cawthorne MA. Nutr Diabetes. 2013 May 27;3:e68.

 

The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders.

Silvestri C, Di Marzo V. Cell Metab. 2013 Apr 2;17(4):475-90.

 

Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes

Di Marzo V, Piscitelli F, Mechoulam R. Handb Exp Pharmacol. 2011;(203):75-104.

 

Cannabinoids inhibit insulin receptor signalling in pancreatic β-cells

Kim W, Doyle ME, Liu Z, Lao Q, Shin YK, Carlson OD, Kim HS, Thomas S, Napora JK, Lee EK, Moaddel R, Wang Y, Maudsley S, Martin B, Kulkarni RN, Egan JM. Diabetes. 2011 Apr;60(4):1198-209.

 

A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans

Romero-Zerbo SY, Rafacho A, Díaz-Arteaga A, Suárez J, Quesada I, Imbernon M, Ross RA, Dieguez C, Rodríguez de Fonseca F, Nogueiras R, Nadal A, Bermúdez-Silva FJ. J Endocrinol. 2011 Nov;211(2):177-85.

 

Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle.

Silvestri C, Ligresti A, Di Marzo V. Rev Endocr Metab Disord. 2011 Sep;12(3):153-62.

 

Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood.

Banni S, Di Marzo V. Mol Nutr Food Res. 2010 Jan;54(1):82-92.

 

Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice.

Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L. Br J Pharmacol. 2009 Apr;156(7):1154-66

 

Lifestyle-induced metabolic inflexibility and accelerated ageing syndrome: insulin resistance, friend or foe?

Nunn AV, Bell JD, Guy GW. Nutr Metab (Lond). 2009 Apr 16;6:16.

 

Endocannabinoids, FOXO and the metabolic syndrome: redox, function and tipping point--the view from two systems.

Nunn AV, Guy GW, Bell JD. Immunobiology. 2010 Aug;215(8):617-28

 

The endocannabinoid system in metabolic control: a preface.

Di Marzo V. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):vii-ix.

 

Cannabidiol arrests onset of autoimmune diabetes in NOD mice.

Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R. Neuropharmacology. 2008 Jan;54(1):244-9

 

Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.

Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, Gallily R. Autoimmunity. 2006 Mar;39(2):143-51.

 

 

Inflammation

 

Cannabidiol in inflammatory bowel diseases: a brief overview.

Esposito G, Filippis DD, Cirillo C, Iuvone T, Capoccia E, Scuderi C, Steardo A, Cuomo R, Steardo L. Phytother Res. 2013 May;27(5):633-6.

 

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.

Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA. Biochem Pharmacol. 2013 May 1;85(9):1306-16.

 

Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability.

Alhamoruni A, Wright KL, Larvin M, O'Sullivan SE. Br J Pharmacol. 2012 Apr;165(8):2598-610.

 

Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.

De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, Di Marzo V. Acta Physiol (Oxf). 2012 Feb;204(2):255-66.

 

Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis.

De Filippis D, Esposito G, Cirillo C, Cipriano M, De Winter BY, Scuderi C, Sarnelli G, Cuomo R, Steardo L, De Man JG, Iuvone T. PLoS One. 2011;6(12):e28159.

 

Cannabis use amongst patients with inflammatory bowel disease.

Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6.

 

Treatment of Crohn's disease with cannabis: an observational study.

Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Isr Med Assoc J. 2011 Aug;13(8):455-8.

 

Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study.

Lahat A, Lang A, Ben-Horin S. Digestion. 2012;85(1):1-8.

 

Gut feelings about the endocannabinoid system.

Di Marzo V, Piscitelli F. Neurogastroenterol Motil. 2011 May;23(5):391-8

 

The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis.

Jamontt JM, Molleman A, Pertwee RG, Parsons ME. Br J Pharmacol. 2010 Jun;160(3):712-23

 

Cannabinoids and the gut: new developments and emerging concepts.

Izzo AA, Sharkey KA. Pharmacol Ther. 2010 Apr;126(1):21-38.

 

Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability.

Alhamoruni A, Lee AC, Wright KL, Larvin M, O'Sullivan SE. J Pharmacol Exp Ther. 2010 Oct;335(1):92-102.

 

Cannabinoids and the immune system: an overview.

Tanasescu R, Constantinescu CS. Immunobiology. 2010 Aug;215(8):588-97.

 

Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.

Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, Guadagno F, Petrosino S, Capasso F, Di Marzo V, Izzo AA. J Mol Med (Berl). 2009 Nov;87(11):1111-21.

 

Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.

Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F, Izzo AA. Br J Pharmacol. 2008 Jul;154(5):1001-8.

 

A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents.

Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, Li K, Li YN, Storr M. Neurogastroenterol Motil. 2011 Sep;23(9):862-e342.

Link:

Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

Blake DR, Robson P, Ho M, et al. Rheumatology (Oxford). 2006;45(1):50-2.

 

 

Oncology

 

Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.

Scott KA, Shah S, Dalgleish AG, Liu WM. Anticancer Res. 2013 Oct;33(10):4373-80.

 

Cannabidiol as potential anticancer drug.

Massi P, Solinas M, Cinquina V, Parolaro D. Br J Clin Pharmacol. 2013 Feb;75(2):303-12

 

Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells through a Multitarget Effect.

Solinas M, Massi P, Cinquina V, Valenti M, Bolognini D, Gariboldi M, Monti E, Rubino T, Parolaro D. PLoS One. 2013 Oct 21;8(10):e76918.

 

Cannabinoids: a new hope for breast cancer therapy?

Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C. Cancer Treat Rev. 2012 Nov;38(7):911-8

 

Towards the use of cannabinoids as antitumour agents.

Velasco G, Sánchez C, Guzmán M. Nat Rev Cancer. 2012 May 4;12(6):436-44.

 

Cannabidiol inhibits angiogenesis by multiple mechanisms.

Solinas M, Massi P, Cantelmo AR, Cattaneo MG, Cammarota R, Bartolini D, Cinquina V, Valenti M, Vicentini LM, Noonan DM, Albini A, Parolaro D. Br J Pharmacol. 2012 Nov;167(6):1218-31.

 

Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.

Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, Di Marzo V, Izzo AA. J Mol Med (Berl). 2012 Aug;90(8):925-34.

 

A combined preclinical therapy of cannabinoids and temozolomide against glioma.

Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M, Velasco G. Mol Cancer Ther. 2011 Jan;10(1):90-103.

 

Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action.

Lorente M, Torres S, Salazar M, Carracedo A, Hernández-Tiedra S, Rodríguez-Fornés F, García-Taboada E, Meléndez B, Mollejo M, Campos-Martín Y, Lakatosh SA, Barcia J, Guzmán M, Velasco G. Cell Death Differ. 2011 Jun;18(6):959-73.

 

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.

McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C, Liu Y, Debs RJ, Moore DH, Desprez PY. Breast Cancer Res Treat. 2011 Aug;129(1):37-47.

 

The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK.

Andradas C, Caffarel MM, Pérez-Gómez E, Salazar M, Lorente M, Velasco G, Guzmán M, Sánchez C. Oncogene. 2011 Jan 13;30(2):245-52

 

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

Caffarel MM, Andradas C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G, Flores JM, García-Real I, Palacios J, Mañes S, Guzmán M, Sánchez C. Mol Cancer. 2010 Jul 22;9:196

 

Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress.

Massi P, Valenti M, Solinas M, Parolaro D. Cancers (Basel). 2010 May 26;2(2):1013-26.

 

Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells.

Salazar M, Carracedo A, Salanueva IJ, Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C, Torres S, García S, Nowak J, Fimia GM, Piacentini M, Cecconi F, Pandolfi PP, González-Feria L, Iovanna JL, Guzmán M, Boya P, Velasco G. J Clin Invest. 2009 May;119(5):1359-72.

 

Cannabinoids in intestinal inflammation and cancer.

Izzo AA, Camilleri M. Pharmacol Res. 2009 Aug;60(2):117-25.

 

Cannabinoids as potential new therapy for the treatment of gliomas.

Parolaro D, Massi P. Expert Rev Neurother. 2008 Jan;8(1):37-49.

 

Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression.

Blázquez C, Salazar M, Carracedo A, Lorente M, Egia A, González-Feria L, Haro A, Velasco G, Guzmán M. Cancer Res. 2008 Mar 15;68(6):1945-52.

 

Cannabinoids and gliomas.

Velasco G, Carracedo A, Blázquez C, Lorente M, Aguado T, Haro A, Sánchez C, Galve-Roperh I, Guzmán M. Mol Neurobiol. 2007 Aug;36(1):60-7.

 

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells.

McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY. Mol Cancer Ther. 2007 Nov;6(11):2921-7.

 

Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis.

Aguado T, Carracedo A, Julien B, Velasco G, Milman G, Mechoulam R, Alvarez L, Guzmán M, Galve-Roperh I. J Biol Chem. 2007 Mar 2;282(9):6854-62.

 

Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.

Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C. Cancer Res. 2006 Jul 1;66(13):6615-21.

 

A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.

Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. Br J Cancer. 2006 Jul 17;95(2):197-203.

 

 

Psychiatric Illness

 

Cannabinoids and Schizophrenia: Therapeutic Prospects.

Robson PJ, Guy GW, Di Marzo V. Curr Pharm Des. 2013 Jun 14. [Epub ahead of print]

 

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.

Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Transl Psychiatry. 2012 Mar 20;2:e94

 

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3364-78.

 

Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies.

Bhattacharyya S, Atakan Z, Martin-Santos R, Crippa JA, McGuire PK. Curr Pharm Des. 2012;18(32):5045-54.

 

Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, Woodcock H, Dorward P, Pigliacampo B, Close S, Platt B, Riedel G. Psychopharmacology (Berl). 2012 Feb;219(3):859-73.

 

Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats.

Gururajan A, Taylor DA, Malone DT. J Psychopharmacol. 2012 Oct;26(10):1317-32.

 

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O' Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Neuropsychopharmacology. 2010 Feb;35(3):764-74.

 

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.

Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Braz J Med Biol Res. 2006 Apr;39(4):421-9.

 

Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice.

Long LE, Malone DT, Taylor DA. Neuropsychopharmacology. 2006 Apr;31(4):795-803.

 

 

Other

 

The propagation, characterisation and optimisation of Cannabis Sativa L as a phytopharmaceutical

PhD thesis, Dr David Potter